Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced bre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaufman, Bella, Stein, Steven, Casey, Michelle A, Newstat, Beth O
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2008
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727787/
https://ncbi.nlm.nih.gov/pubmed/19707428
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars